CA
ALXN

Commerzbank Aktiengesellschaft’s Alexion Pharmaceuticals ALXN Stock Holding History

Commerzbank Aktiengesellschaft’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,247
Closed -$561K – 448
2020
Q1 		$561K Sell
6,247
-14,200
-69% -$1.39M 0.03% 251
2019
Q4 		$2.21M Sell
20,447
-128,587
-86% -$13.8M 0.02% 324
2019
Q3 		$14.6M Buy
149,034
+13,237
+10% +$1.49M 0.11% 151
2019
Q2 		$17.8M Buy
135,797
+12,474
+10% +$1.61M 0.14% 126
2019
Q1 		$16.7M Sell
123,323
-95,365
-44% -$11.9M 0.15% 122
2018
Q4 		$21.3M Buy
218,688
+125,344
+134% +$14.8M 0.22% 87
2018
Q3 		$13M Sell
93,344
-5,433
-6% -$682K 0.11% 152
2018
Q2 		$12.3M Sell
98,777
-12,648
-11% -$1.48M 0.12% 154
2018
Q1 		$12.4M Sell
111,425
-37,914
-25% -$4.53M 0.13% 153
2017
Q4 		$17.9M Sell
149,339
-431
-0.3% -$52.5K 0.2% 101
2017
Q3 		$21M Buy
149,770
+17,072
+13% +$2.32M 0.28% 85
2017
Q2 		$16.1M Buy
132,698
+79,943
+152% +$9.3M 0.27% 89
2017
Q1 		$6.4M Buy
52,755
+40,916
+346% +$5.28M 0.09% 183
2016
Q4 		$1.45M Buy
11,839
+7,416
+168% +$907K 0.02% 379
2016
Q3 		$542K Sell
4,423
-6,942
-61% -$894K 0.01% 548
2016
Q2 		$1.33M Sell
11,365
-9,243
-45% -$1.31M 0.01% 430
2016
Q1 		$2.87M Sell
20,608
-61,759
-75% -$9.07M 0.02% 315
2015
Q4 		$15.7M Buy
82,367
+1,285
+2% +$224K 0.12% 140
2015
Q3 		$12.7M Sell
81,082
-51,247
-39% -$9.35M 0.1% 142
2015
Q2 		$23.9M Buy
132,329
+4,475
+4% +$772K 0.13% 112
2015
Q1 		$22.2M Buy
127,854
+2,136
+2% +$387K 0.13% 117
2014
Q4 		$23.3M Sell
125,718
-10,770
-8% -$2M 0.15% 115
2014
Q3 		$22.6M Buy
136,488
+23,831
+21% +$3.91M 0.09% 174
2014
Q2 		$17.6M Buy
112,657
+8,928
+9% +$1.41M 0.09% 178
2014
Q1 		$15.8M Sell
103,729
-2,653
-2% -$422K 0.07% 181
2013
Q4 		$16.9M Sell
106,382
-20,815
-16% -$2.5M 0.08% 164
2013
Q3 		$14.8M Buy
127,197
+3,155
+3% +$346K 0.07% 204
2013
Q2 		$11.4M Buy
+124,042
New +$12M 0.05% 284

Other funds holding ALXN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Commerzbank Aktiengesellschaft's ALXN Position: Q2 2020 in Review

Commerzbank Aktiengesellschaft sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 6,247 shares — an estimated $561K sold.

Commerzbank Aktiengesellschaft first reported a position in ALXN in Q2 2013 and held it in 28 quarters. The position peaked at $23.9M in Q2 2015. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

  • Commerzbank Aktiengesellschaft reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Commerzbank Aktiengesellschaft sold 6,247 Alexion Pharmaceuticals shares in Q2 2020, an estimated $561K.
  • Commerzbank Aktiengesellschaft first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 28 quarters.
  • Commerzbank Aktiengesellschaft's Alexion Pharmaceuticals position peaked at $23.9M in Q2 2015.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q2 2020, filed 21 Jul 2020.